荧光磁性纳米粒子标记的小鼠胚胎干细胞靶向识别体内胃癌细胞

胃癌的早期诊断和治疗是提高胃癌患者预后的关键, 纳米技术和干细胞是继手术、化疗和放疗之外新兴的肿瘤治疗新技术. 制备了氨基化修饰的荧光磁性纳米粒子(FMNPs), 无滋养层培养了小鼠胚胎干细胞(mESCs), 体外实验评价了mESCs的条件培养基对胃癌细胞的影响, 并利用FMNPs标记mESCs制备了干细胞纳米探针(FMNPs-mESCs), 通过尾静脉注射进入荷瘤小鼠的体内, 利用小动物活体成像系统考察了FMNPs-mESCs靶向识别体内胃癌细胞的能力. 结果显示, 制备的FMNPs具有良好的荧光性能和磁响应性能, 在50 μg/mL的浓度范围内对mESCs具有良好的生物活性, mESCs的条件培养基对胃癌细胞具有显著的抑制增殖的作用, FMNPs标记的mESCs具有良好的荧光性能, 在注射进入荷瘤小鼠体内6 h后可以通过活体成像结果和离体器官的荧光成像结果观察到肿瘤组织有显著的荧光信号. 研究表明, FMNPs-mESCs具有特异靶向识别体内胃癌细胞的能力, 为利用胚胎干细胞治疗胃癌提出新的研究方向.

Fluorescent magnetic nanopaticles-labeled murine embryonic stem cells for targeted identification of in vivo gastric cancer cells

Early diagnosis and therapy is crucial to improve prognosis of gastric cancer patients. Nanotechnology and stem cell technology are two emerging new technologies to treat cancer following operation therapy, chemotherapy and radiotherapy. In this work, amino- modified silica-coated fluorescent magnetic nanoparticles (FMNPs) were prepared; feeder-free murine embryonic stem cells (mESCs) were cultured; the effect of mESCs-conditioned medium ongastric cancer cells were evaluated in vitro; the mESCs were labeled with FMNPs to make the stem cell nanoprobes (FMNPs-mESCs); and the abitlity of FMNPs-mESCs targeted indentifing in vivo gastric cancer cells were monitored by IVIS imaging system after the FMNPs-mESCs were intravenously injected into gastric tumor-bearing mice. The results show that the prepared FMNPs have high fluorescent and magnetic resonance performances; FMNPs within dose of 50 μg/mL exhibited good biocompability to mESCs; mESCs-conditioned medium displayed significantly inhibitory effects on the growth of gastric cancer cells; and after the FMNPs-mESCs were injected into gastric tumor-bearing mice 6 h, from in vivo and ex-vivo imaging results we could observe that gastric cancer tissues have significantly fluorescent signals. These results demonstrate that FMNPs-mESCs have the ability of targeted identifing in vivo gastric cancer cells. It also provides the new research field for therapy gastric cancer using embryonic stem cells.